Medical Biomimetics Market Size, Share & Trends Analysis Report By Type (Cardiovascular, Orthopedic, Ophthalmology), By Application (Wound Healing, Tissue Engineering, Drug Delivery), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global medical biomimetics market size was valued at USD 29.21 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.7% from 2022 to 2030. Biomimetics is an integrative area in which principles from biology, chemistry, and engineering are used for the synthesis of materials, machines or synthetic systems that have functions that imitate the biological processes. Biomimetics based designs could be used in drug delivery, tissue engineering, and regenerative medicine. The application of biomimetics to illustrate the issues in pharmaceutics and medicine is a promising method for the treatment of deadly diseases like cancer. The fast growth of medical biomimetics market is mainly driven by the increasing government funding for research pertaining to biomimetics, along with adoption and innovations of medical engineering and nanotechnology in healthcare.

The medical biomimetics market was affected by COVID-19 owing to delays and cancellations of orthopedic, dental, cardiovascular, and other medical procedures. However, the development of vaccines, medicines, and conventional drugs, in addition to the use of innovative drug delivery technologies has increased impetus in the fight against the COVID-19 pandemic. Advanced delivery technologies, such as the use of nanocapsules/ nanospheres, nanocrystals, liposomes, nano lipid carriers/solid lipid nanoparticles, nanosponges and dendrimers based on biomimetics can be utilized for targeted delivery of therapeutic compounds to infected individuals for treating COVID-19. Numerous research activities have been carried out for the use of biomimicry during the pandemic. For instance, in August 2021, researchers from Academy of Medical Engineering and Translational Medicine, School of Life Sciences and Tianjin University designed the inhalable nanovaccine with biomimetics COVID-19 structure to activate the mucosal immunity of respiratory tract against coronavirus. Through replicating the route of infection and structure, this inhalable nanovaccine approach might encourage a new approach for the respiratory viruse precaution.

Medical biomimetics is the fastest expanding field of bioengineering. It is the impersonation of features found in animals and plants to provide both treatment and protection from bacteria and illness as well as management of disease. Medical biomimetics is considered a technology that emulates or uses nature for the advancement of the human lives. Medical biomimetics is gaining more adoption in surgical devices and instruments development. For instance, in September 2021, Nexa3D, partnered with Henkel to develop the world’s first connected SKOP stethoscope for WeMed. Based on the biomimetics design and developed on the NXE400 3D printer using materials from Henkel, the WeMed SKOP stethoscope is the first connected stethoscope to be manufactured additively.

There has been increase in the use of biomimetics in tools and devices for artificial creation of organs mainly due to susceptibility of old age people for organ dysfunction and failure. Increasing awareness and adoption of biomimetics has had a positive impact on organ transplantation and will continue to push the market growth in forthcoming years. Efforts to encourage organ donation must continue in all countries, but it is also necessary to develop alternative solutions, such as bioengineering. Various companies are involved in the development of biomimetics based products. For instance, CorNeat Vision developed CorNeat KPro implant, a patented synthetic cornea, which offers a long-lasting medical solution for corneal injury, and blindness. The product is following a CE marking and 510K clearance path, which is expected to be approved for marketing in late 2024. In addition, the company in October 2021 also received USD 2.44 million grant by the European Innovation Council to support the clinical activities as well as automation and manufacturing processes which will enable the company to reach the market with this cure.

Moreover, the innovations in nanotechnology, leading to the advancement in drug delivery systems will positively impact the medical biomimetics growth in the forecast period. Based on their biocompatibility physical, and chemical properties, nanomaterials are attractive for use in biomedical applications and exhibit great possibility in biomimetics medicine. Currently, with the advancement of biomimetic functionalized nanotechnology, nanomaterials have been functionalized and modified by cell membrane-derived elements to form biomimetic nanomaterials with augmented biocompatibility, stability, targeting, and specificity. The biomimetic functionalized variation of nanomaterials can establish selectivity for tissue disease or biomarkers, implying that these biomimetic nanomaterials can be used for the diagnosis of disease. Thus, the use of biomimetic nanomaterials for the non-invasive diagnosis of diseases has stimulated great interest.

Additionally, rising R&D activities coupled with the growing application potential of medical biomimetics in the diagnostic imaging market space including ultrasound, ECGs, and CT scans are expected to drive the market growth. For instance, Imperial College London is currently developing biomimetic flexible steerable probe. The objective of this research is to access deep brain areas with the least damage to precisely place the minimally invasive instrumentation (electrodes, catheters for deep stimulation of brain), to perform the diagnosis and clinical analysis (sampling, biopsy), micro neurosurgery, and localized drug delivery.

Type Insights

The cardiovascular segment dominated the medical biomimetics market and accounted for the largest revenue share of 42.4% in 2021. CVD is the number one cause of death globally, affecting 17.9 million deaths every year. Worldwide, more than 2.1 million patients receive CVD implants each year to prevent death. Moreover, the launch of technologically advanced products coupled with government funding offers lucrative opportunities for the segment during the forecast period.

LifeMatrix has developed a distinctive bioengineering technology to grow human replacement tissues as next-generation implants for treating CVDs. The patented LifeMatrix tissues can be manufactured as blood vessels, heart valves, and other cardiovascular structures. The biomimetic device helps to prevent repetitive major surgeries and the risks associated with them throughout the patient’s life. In addition, the technology which has been created by a team of cardiovascular and cardiac experts in April 2021 also received USD 149707 funding from Venture Kick to support regulatory submissions and increase the clinical launch strategy.

Orthopedic segment is expected to grow at the fastest CAGR of the medical biomimetics market during the forecast period. Technological advancements coupled with the launch of new products drive the growth of the segment. For instance, in March 2021, Sparta Biomedical Inc., received Breakthrough Device Designation from the USFDA for SBM-01 Biomimetic Implant. The implant is proposed to replace the damaged knee cartilage in patients suffering from single or multiple osteochondral or chondral defects in the knee. The company, in December 2021, also received USD 5 Million to advance its preclinical activities for investigational device exemption submission.

Application Insights

The wound healing segment dominated the medical biomimetics market and accounted for the largest revenue share of 34.59% in 2021. The demand for wound healing and wound care products is growing, owing to the escalating number of surgical cases and the increasing prevalence of chronic diseases globally. Moreover, the segment will continue to grow due to specific demographic trends, with an aging population, rising incidence of diabetes and obesity, and related higher sensitivity towards non-healing chronic wounds. In the U.S., in 2021, the prevalence of chronic wounds was about 2% of the overall U.S. population, or about 6.9 million people were suffering from chronic wounds. Furthermore, the expanding number of patients needing improved treatment represents a considerable burden of cost on the healthcare system. The total cost for treating chronic wounds is increasing sharply, and the recent annual projected cost in the U.S. exceeds USD 28 billion.

While numerous approaches for wound healing are offered, they are only somewhat effective. Thus, there is a demand for more efficient therapies for healing wounds. Advancement of instructive materials and biomimetics is evolving as a favorable procedure for redirecting fibrotic wound healing into a regenerative method. Biomimetics materials are currently advancing on the shortcomings of current treatments for wound care as they are being created to accelerate these spatiotemporal cues, thus encouraging regeneration within the host tissues.

The drug delivery segment is anticipated to witness a considerable growth rate in the medical biomimetics market during the forecast period. This can be attributed to the patient shifts towards the adoption of advanced drug administration systems, and increasing research and development. So far, albumin-based delivery is perhaps the most successful approach of biomimetics therapeutics, and there are numerous marketed drugs involving abraxane, liraglutide, semaglutide and, albiglutide. In addition, cell-based biomimetic delivery is other interesting cases for biomimetics therapeutics. For instance, since 1970s RBC as living cell carriers have been examined for decades.  Moreover, the adoption of targeted drug delivery systems further promotes the growth of biomimetic in drug delivery application as biomimetics approaches show promising results in promoting drug efficiency in targeted drug delivery.

Regional Insights

North America dominated the regional medical biomimetics market with a share of 38.71% in 2021. The large share is mainly attributed to the high research and development activities in the region, high adoption of novel technology, high disposable income, and presence of key market players in the region.

Asia Pacific region is projected to exhibit a high growth rate of medical biomimetics market during the forecast period owing to increasing investment in medical and healthcare infrastructure, huge patient population, growing awareness and adoption of new technology, and government initiatives to boost the growth of the biotechnology sector.

Key Companies & Market Share Insights

Key players in medical biomimetics are implementing various strategies including partnerships through mergers and acquisitions, geographical expansion, and strategic collaborations to expand their market presence. For instance, in February 2022, NanoHive Medical, LLC a leader in the innovation of 3D printed, biomimetic spinal interbody fusion solutions, announced a distribution agreement with Accelus. The agreement helps in developing the distribution network for NanoHive Medical’s Hive Soft Titanium range of interbody fusion devices in the U.S. Some of the key players in the global medical biomimetics market include:

• Otsuka Medical Devices Group

• Stryker

• Abbott

• AVINENT Science and Technology

• SynTouch Inc

• Osteopore International Pte Ltd

• Vandstrom, Inc.

• Biomimetics Technologies Inc

• Swedish Biomimetics 3000 ApS

• Keystone Dental Group

• LifeMatrix

• Curasan, Inc. 

• CorNeat Vision 

• NanoHive Medical LLC

• Zimmer Biomet

Recent Developments

• In November 2021, Otsuka Medical Devices Co., Ltd. launched the BioMimics 3D Vascular Stent System. This product helped with the treatment of acute blockage associated with unsuccessful treatment of a patient.

Medical Biomimetics Market Report Scope

Global Medical Biomimetics Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global medical biomimetics report on the basis of type, application, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Cardiovascular

  • Orthopedic

  • Ophthalmology

  • Dental

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Wound Healing

  • Tissue Engineering

  • Drug Delivery

  • Other Applications

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE